The FDA sent a warning letter to Thang Botanicals, Inc., the company behind a Strawberry Acai product labeled “7-Hydroxymitragynine Gummies,” concluding that the candy-flavored gummies contain added 7-hydroxymitragynine, or 7-OH, derived from kratom extract. That letter was one of seven the agency issued to firms selling concentrated 7-OH in consumer-friendly formats. Days later, the DEA announced its intent to temporarily place 7-OH into Schedule I, citing high abuse potential and no accepted medical use. Together, the actions represent the most aggressive federal crackdown yet on a class of kratom-derived products that regulators say look and taste like ordinary candy.
Why concentrated 7-OH gummies triggered a federal response
The FDA’s enforcement push centers on a sharp distinction: the trace amounts of 7-OH found naturally in kratom leaf versus the far higher concentrations packed into commercial gummies, drink mixes, and pills. FDA Commissioner Marty Makary spelled out that difference in a Dear Colleague Letter sent to health professionals, warning that concentrated 7-OH products are sold as “pills, gummies, candies” and other eye-catching forms that carry opioid-level risks well beyond anything associated with traditional leaf preparations.
The agency’s position is that 7-OH has never been approved as a food additive, is not generally recognized as safe, and cannot lawfully appear in dietary supplements or conventional foods. That legal framework turned each candy-flavored product into an adulterated food the moment its manufacturer added concentrated 7-OH or kratom extract. The warning letter to Thang Botanicals laid out this reasoning in detail, identifying the Strawberry Acai gummies by name and concluding the 7-OH content could only have come from added kratom extract.
The concern is not abstract. Products designed to look and taste like fruit snacks lower the barrier to casual use, particularly among younger consumers who may not associate a gummy with opioid-receptor activity. The FDA’s July 2025 report on 7-OH compiled receptor-binding data and abuse-potential findings to support the view that concentrated formulations pose qualitatively different risks than chewing raw kratom leaf. Whether those risks translate into measurably higher emergency-department visits once scheduling takes effect is a question poison-control data should eventually answer, but no granular case counts tied specifically to 7-OH gummies have been published so far.
Regulators are also focused on how these products are marketed. Bright packaging, candy flavors, and online promotion alongside ordinary supplements can blur the line between a casual wellness product and a substance that behaves like a potent opioid at relevant doses. Makary’s letter urged clinicians to ask patients directly about 7-OH products when taking substance-use histories, noting that patients may not volunteer information about “gummies” they do not recognize as drugs.
Seven warning letters and a Schedule I filing
The FDA did not single out one company. The agency publicly announced seven warning letters targeting firms that marketed concentrated 7-OH products. Beyond Thang Botanicals, one letter went to Royal Diamond Imports, Inc. for a passion-fruit flavored drink mix containing 7-OH supplied through added kratom extract. That letter applied the same legal logic: no food-additive authorization, no GRAS status, and therefore an adulterated product. Royal Diamond was also cited for making unapproved drug claims on its website.
In its broader statement, the FDA framed the crackdown as a necessary step to keep an emerging class of opioid-like products from becoming normalized in convenience stores and vape shops. Officials emphasized that companies had been formulating 7-OH into gummies, candies, and drink sticks that resemble energy products or vitamin chews, not prescription medications. That presentation, the agency argued, heightens the risk of accidental overuse and makes it harder for parents and clinicians to recognize what a child or patient has actually consumed.
The DEA then escalated the regulatory pressure on July 1, 2026, announcing its intent to temporarily place 7-OH into Schedule I. The agency cited its own lab findings confirming that commercial 7-OH products contain the substance and pointed to a lack of accepted medical use alongside high abuse potential as the basis for scheduling. Temporary Schedule I placement would make possession and sale of concentrated 7-OH products a federal crime, a far sharper tool than the FDA’s food-safety enforcement letters.
The two agencies are working in sequence. The FDA built the scientific and legal case through its toxicological assessment, warning letters, and Commissioner Makary’s outreach to clinicians. The DEA then used that foundation to justify controlled-substance action. For manufacturers, the combined effect is a closing window: companies that received warning letters face immediate compliance demands from the FDA, and once temporary scheduling takes effect, the products themselves become illegal to distribute.
That sequencing also shapes what happens to products already on shelves. Retailers that stocked 7-OH gummies or drink mixes based on supplier assurances that they were “legal” dietary supplements now have to reassess inventory. Under the Food, Drug, and Cosmetic Act, the FDA can pursue distributors of adulterated foods even if they did not manufacture the items. Once the DEA’s temporary rule is in force, law enforcement agencies gain an additional basis to seize stock and bring criminal cases for knowing distribution of a Schedule I substance.
Gaps in the evidence and what consumers should watch
Several questions remain open. The FDA’s enforcement letters and scientific report establish that concentrated 7-OH activates opioid receptors and carries abuse potential, but the agency has not released adverse-event database extracts or specific case counts linking 7-OH gummies to hospitalizations. Without that data, the precise scale of harm from these products is difficult to measure against leaf-based kratom, which has its own history of poison-control reports. Peer-reviewed pharmacokinetic studies comparing commercial gummy dosing to leaf consumption are also limited in granularity.
Thang Botanicals and the other warned firms now face a choice: reformulate without 7-OH, challenge the FDA’s interpretation, or exit the market entirely. The agency’s letters typically give companies 15 working days to respond with corrective steps. While firms can argue that their products fill a demand among adults who already use kratom, the lack of food-additive approval leaves little room to negotiate over current formulations. Any attempt to defend 7-OH as a lawful dietary ingredient would run headlong into the FDA’s position that it has not been shown to be safe under the conditions of intended use.
For consumers, the most immediate takeaway is caution. Products marketed with terms like “7-OH,” “7-hydroxy,” or “enhanced kratom extract” are likely to be directly affected by the new enforcement posture. Even before DEA scheduling takes effect, FDA warning letters signal that regulators view these items as unsafe and unlawfully marketed. People who have been using 7-OH gummies daily may be at risk of withdrawal symptoms if they stop abruptly, given the compound’s opioid-receptor activity, and should discuss tapering strategies with a healthcare professional rather than quitting on their own.
Parents and caregivers should also be aware that 7-OH products may not be clearly labeled as opioids or controlled-substance analogues. Packaging that emphasizes fruit flavors or “plant-based” ingredients can obscure the pharmacological reality. Checking ingredient lists for references to 7-hydroxymitragynine or kratom extract, and treating unfamiliar gummies or drink sticks with the same skepticism reserved for unmarked pills, is a practical starting point.
Looking ahead, the regulatory picture is likely to evolve. Temporary Schedule I status can last for up to several years while the DEA gathers additional data and considers permanent scheduling. During that period, researchers who wish to study 7-OH’s pharmacology or potential therapeutic uses will face the same licensing and security hurdles that apply to other Schedule I substances. Advocates for kratom and its derivatives are expected to press for clearer distinctions between traditional leaf products and highly concentrated extracts, but the current federal actions leave little doubt that candy-like 7-OH formulations are squarely in regulators’ crosshairs.
In the meantime, the combination of FDA enforcement and impending DEA scheduling sends a clear signal: 7-OH gummies and similar products are being treated not as benign wellness trends but as unapproved, opioid-like substances packaged in deceptively friendly forms. Until more transparent safety data emerge-and unless regulators reverse course-consumers, clinicians, and retailers should approach these products with a level of caution that matches that assessment.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
